Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based assays, FISH testing and other molecular diagnostics, announces receipt of a Notice of Allowance for U.S. Patent Application No. 13/856,190, entitled, “Methods and materials for classification of tissue of origin of tumor samples.”
Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Pembrolizumab Presented at AACR Annual Meeting and Published in the New England Journal of Medicine
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from KEYNOTE-001, a Phase 1b study evaluating pembrolizumab, the company’s investigational anti-PD-1 therapy, in naïve and previously-treated patients with advanced non-small cell lung cancer (NSCLC). In a new analysis of 313 patients from a validation data set for tumour PD-L1 expression, overall-response rate (ORR) was 45.4 percent (95% CI, 33.5-57.3) in patients with greater than or equal to (>=) 50 percent of tumour cells positive for PD-L1 expression (n=73). In the other PD-L1 subgroups, ORR was 16.5 percent (95% CI, 9.9-25.1) in patients with 1-49 percent tumour cells positive (n=103) and 10.7 percent (95% CI, 2.3-28.2) in patients with less than1 percent tumour cells positive (n=28) for PD-L1 expression. In the total study population, ORR was 19.4 percent (95% CI, 16.0-23.2) (n=495), which was consistent with data previously presented from this study. These data from KEYNOTE-001 will be presented today by Dr. Edward Garon, Jonsson Comprehensive Cancer Center, University of California, Los Angeles at the American Association for Cancer Research (AACR) Annual Meeting (abstract #CT104), were part of the AACR press program, and were also published today in the New England Journal of Medicine.
Ventana Medical Systems, Inc. and Astellas Pharma Join Forces to Leverage Novel Companion Diagnostic Tests for Targeted Cancer Treatments
Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, recently announced it has entered into master collaboration agreement with Astellas Pharma Inc., an R&D-driven global pharmaceutical company headquartered in Japan, to develop novel automated tissue diagnostics in support of therapeutic compounds in development.
Adaptive Biotechnologies’ clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA
Adaptive Biotechnologies recently announced publication of a study in The Lancet Oncology showing that analysis of circulating tumor DNA (ctDNA) using the company’s next-generation sequencing-based minimal residual disease (MRD) detection and quantification technology (available clinically as the clonoSEQ™ MRD test) accurately identifies patients with diffuse large B-cell lymphoma (DLBCL) who are at risk of relapse after initial treatment, usually several months before disease can be detected via computed tomography (CT). The study, conducted with collaborators from the National Cancer Institute (NCI), suggests that the clonoSEQ MRD test may ultimately replace the imaging techniques currently used for DLBCL disease monitoring, which are imprecise and expose patients to radiation.
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, recently announced that it has initiated a pilot study to assess the feasibility of VolitionRx’s proprietary NuQ® assays in detecting prostate cancer. The study is in collaboration with ImmuneHealth, a global biomarker contract research organization (CRO), and is taking place in Belgium.